Development of adenoviral vectors armed with TNF-related therapeutic proteins for gene therapy

Keyphrases

• Adenosine Deaminase Deficiency 33%
• Adenoviral Vector 100%
• Adenovirus 33%
• AIDS/HIV 33%
• Apoptosis Evasion 33%
• Apoptosis-inducing Activity 33%
• Cancer Cell Migration 33%
• Cancer Cells 33%
• Cancer Therapeutics 33%
• COVID-19 33%
• FasL 33%
• Fibrosis 66%
• Gene Therapy 100%
• Genetic Disease 33%
• Genetic Material 33%
• Genetic Origin 33%
• Healthy Cells 33%
• In Cancer 66%
• Induced Apoptosis 33%
• Inducing Ligand 33%
• Infectious Diseases 33%
• Ligand-protein 33%
• Monogenic Disease 33%
• NF-B 33%
• Patient Cells 33%
• Potential Therapeutics 33%
• Proliferative Signaling 33%
• RANKL Protein 33%
• Spinal muscular Atrophy 33%
• Therapeutic Effect 33%
• Therapeutic Proteins 100%
• Tumor Necrosis Factor Family 66%
• Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) 100%
• Tumor Necrosis Factor-α 100%

Biochemistry, Genetics and Molecular Biology

• Adenosine Deaminase 20%
• Adenoviridae 20%
• Adenovirus Vector 100%
• Cancer Cell 40%
• Cell Migration 20%
• Eicosanoid Receptor 20%
• Gene Therapy 100%
• Genetic Disorder 20%
• Genetics 40%
• Human Immunodeficiency Virus 20%
• RANK 20%
• RANKL 40%
• Therapeutic Protein 100%
• Tumor Necrosis Factor 100%
• Tumor Necrosis Factor Family 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenosine Deaminase Deficiency 16%
• Adenoviridae 16%
• Adenovirus Vector 100%
• Antiinfective Agent 16%
• Disease 33%
• Fibrosis 33%
• Genetic Disorder 16%
• HIV 16%
• Infection 16%
• Malignant Neoplasm 100%
• Osteoclast Differentiation Factor 33%
• Receptor 16%
• Side Effect 16%
• Spinal Muscular Atrophy 16%
• Therapeutic Effect 16%
• Tumor Necrosis Factor 100%
• Tumor Necrosis Factor Related Apoptosis Inducing Ligand 50%